Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618479 | 0.87 | THRB (0.42) | THRBTP53 | |
| SCHEMBL17618477 | 0.86 | BRAF (0.40) | CNR1MAPTTHRBTP53LRRK2 | |
| SCHEMBL19706065 | 0.85 | RPS6KA3 (0.38) | RPS6KA3RPS6KA2CNR1MAPTSMN1; SMN2 | |
| SCHEMBL17618482 | 0.84 | HDAC2 (0.39) | CNR1MAPTTHRBTP53LRRK2 | |
| SCHEMBL17618486 | 0.83 | LRRK2 (0.38) | TP53LRRK2JAK2JAK1USP30 | |
| SCHEMBL16238326 | 0.82 | CACNA1G (0.40) | CNR1MAPTTHRBLRRK2USP30 | |
| SCHEMBL17770603 | 0.82 | CACNA1G (0.40) | CNR1MAPTTHRBLRRK2USP30 | |
| SCHEMBL17618505 | 0.82 | CACNA1G (0.40) | CNR1MAPTTHRBLRRK2USP30 | |
| SCHEMBL17618489 | 0.82 | THRB (0.44) | THRBTP53LRRK2USP30 | |
| SCHEMBL17618483 | 0.81 | KDM1A (0.37) | CNR1MAPTTHRBTP53LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IDO1 1229/4885RPS6KA3 2368/4885RPS6KA2 2318/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | IDO1 1229/4885RPS6KA3 2368/4885RPS6KA2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.